

October 26, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Press Release – Q2 & H1 FY27

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find enclosed herewith the Press Release on Financial Results of the Company for the Q2 & H1 FY27.

The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

HITESH

KUMAR JAIN

Hitesh Kumar Jain

**Company Secretary &
Compliance Officer**

Digitally signed by
HITESH KUMAR JAIN
Date: 2026.10.26
15:21:50 +05'30'

Encl.: A/a

Press Release

Strong Revenue growth of 17%; EBITDA up by 27% and PAT up by 38%; Domestic Business¹ delivered robust growth of 16%

New Delhi, India, 26th October, 2026: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India's fourth largest pharmaceutical Company today announced its financial results for the second quarter and half year ended 30th September 2026. The information mentioned in this release is based on consolidated financial statements.

<u>Q2 FY27</u>	Revenues INR 4,338 Crore 17% YoY ↑	Dom. Revenue¹ INR 3,428 Crore 16% YoY ↑	EBITDA INR 1,175 Crore 27% YoY ↑
<u>H1 FY27</u>	Revenues INR 8,368 Crore 15% YoY ↑	Dom. Revenue¹ INR 6,608 Crore 13% YoY ↑	EBITDA INR 2,235 Crore 26% YoY ↑

Mr. Rajeev Juneja – Vice Chairman & Managing Director

- Revenue grew ~17% YoY with EBITDA margins improving by 210 bps to 27.1%
- Strong domestic business¹ growth of 15.9% led by 1.2x volume outperformance to IPM, further supported by:
 - ✓ Mid-teen growth in Mankind Domestic with 1.1x Chronic outperformance², led by growth of 19% in Cardiac and 16% in Anti-diabetes
 - ✓ Acute outperformance of 1.1x, led by 19% growth in Gastro, 26% in VMN
 - ✓ Steady double digit growth in BSV domestic specialty business
- International business grew 33%, while OTC witnessed muted growth in Q2
- Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics, marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth.

1. Domestic business excluding Consumer Healthcare || 2. Ex-Tirzepatide

Press Release

Q2 FY27 Performance Summary

- Revenue from Operations at INR 4,338 Cr, up by 17.3%YoY
 - Domestic revenue at INR 3,657 Cr, up 14.8%, Exports at INR 681 Cr, up 32.7% YoY
- EBITDA margin of 27.1%, up by 210 bps YoY and PAT margin of 16.5%, up 240 bps YoY
- Diluted EPS¹ of INR 17.2, up 38.9% YoY (FV Re.1)

H1 FY27 Performance Summary

- Revenue from Operations at INR 8,368 Cr, up by 15.1%YoY
 - Domestic revenue at INR 7,082 Cr, up 12.7%, Exports at INR 1,286 Cr, up 31.0% YoY
- EBITDA margin of 26.7%, up by 230 bps YoY and PAT margin of 15.4%, up 210 bps YoY
- Diluted EPS¹ of INR 30.9, up 34.6% YoY (FV Re.1)

1. Diluted EPS not annualised

Domestic Business¹

- Domestic revenue (ex CH)² increased 15.9% YoY driven by strong double digit growth in both Mankind and BSV specialty business
- Secondary sales growth of 15.7% vs 14.2% IPM³ in Q2FY27 indicating a 1.1x outperformance to IPM led by:
 - ✓ 1.1x outperformance in chronic³ growth supported by 18.7% in Cardiac and 15.8 % in Anti-diabetes
 - ✓ 1.1x outperformance in acute driven by Gastro (1.3x), VMN 1.4x); Anti-infectives also recovering QoQ (5.4% in Q2FY27 vs 3.6% in Q1FY27)
- Strong growth in key focused brands:
 - ✓ Acute brands like Pantakind (31%), Dydroboon (19%), Cefakind CV (18%), Nurokind LC (18%) in Q2FY27
 - ✓ Chronic brands like Pangraf (60%), Placida (28%), Telmikind AM (16%), Glizid M (15%)
 - ✓ Healthy growth in BSVs key brands - Humog (51%), Lonopin (45 %), Anti D (37 %) and ASVS (45%)
 - ✓ Brands with sales above Rs 50 crore increased to 63 in MAT Sep'26 from 54 in FY26, while brands with sales over Rs 100 crore rose to 26 from 22
- Consistently maintained #1 rank over last 9 years with prescription share of 15.2% and prescriber penetration of 84.4% in MAT Aug'26

1.As per IQVIA Sep-2026 // 2.Denotes reported number// 3. Ex-Tirzepatide

Consumer Healthcare Business¹

- Revenue growth impacted by slower offtake in category for the industry and some regional impact in East and South
- Despite softer growth, we gained market share in key Brands – Manforce, and Pregarnews
- MT & E-Com share increased to 18% in Q2FY27 as compared to 12% in Q2FY26 supported by 55% growth
- Healthy growth in secondary sales for Pregarnews and Ova news of 14% and 10% YoY respectively in Q2 FY27

1 As per IQVIA / IQVIA Retail Sep-2026

Press Release

Exports

- International revenue increased by 33% in Q2FY27 driven by strong growth in both Mankind and BSV International
- Mankind has launched 1 new product in Q2FY27 taking the total launched products to 50 in US

Consolidated Profit & Loss Account

Particulars (In INR Crore)	Q2 FY27	Q2 FY26	YoY%	Q1 FY27	QoQ%
Revenue from Operations	4,338	3,697	17.3%	4,031	7.6%
<i>Gross Margins %</i>	<i>72.2%</i>	<i>71.3%</i>	<i>90 bps</i>	<i>72.8%</i>	<i>(60 bps)</i>
EBITDA	1,175	924	27.2%	1,060	10.8%
<i>EBITDA Margin %</i>	<i>27.1%</i>	<i>25.0%</i>	<i>210 bps</i>	<i>26.3%</i>	<i>80 bps</i>
PAT	716	520	37.7%	574	24.7%
<i>PAT Margin %</i>	<i>16.5%</i>	<i>14.1%</i>	<i>240 bps</i>	<i>14.2%</i>	<i>230 bps</i>

Particulars (In INR Crore)	H1 FY27	H1 FY26	YoY%
Revenue from Operations	8,368	7,268	15.1%
<i>Gross Margins %</i>	<i>72.5%</i>	<i>70.9%</i>	<i>160 bps</i>
EBITDA	2,235	1,774	26.0%
<i>EBITDA Margin %</i>	<i>26.7%</i>	<i>24.4%</i>	<i>230 bps</i>
PAT	1,290	965	33.7%
<i>PAT Margin %</i>	<i>15.4%</i>	<i>13.3%</i>	<i>210 bps</i>

Segmental Revenue Break Up

Particulars (In INR Crore)	Q2 FY27	Q2 FY26	YoY%	Q1 FY27	QoQ%
Domestic	3,657	3,184	14.8%	3,426	6.7%
• Domestic (Ex-CH)	3,428	2,958	15.9%	3,180	7.8%
• Consumer Healthcare	229	226	1.2%	246	(7.0%)
Exports	681	513	32.7%	605	12.6%
Total	4,338	3,697	17.3%	4,031	7.6%

Particulars (In INR Crore)	H1 FY27	H1 FY26	YoY%
Domestic	7,082	6,285	12.7%
• Domestic (Ex-CH)	6,608	5,822	13.5%
• Consumer Healthcare	475	463	2.6%
Exports	1,286	982	31.0%
Total	8,368	7,268	15.1%

Press Release

Earning Concall Details

Date	26 th October, 2026
Time	05:00 pm – 06:00 pm IST
Zoom Link	Click here

About Mankind Pharma

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women's health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists.

For more information, visit www.mankindpharma.com

Safe Harbour Statement

The statements, are as on date and may contain forward-looking statements like the words "believe", "expects", "anticipate", "aim", "will likely result", "Would", "will continue", "contemplate" "intends", "plans", "estimates", "seek to", "future", "objective", "projects", "goal", "likely", "Project", "should", "potential" "will", "may", "targeting" or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward- looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic

Press Release

conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance

The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, Company assume no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise.

For Queries Contact

Mankind Pharma - Investor Relations

Prakash Agarwal

Email address: investor.relations@mankindpharma.com

Contact Number: +91-11-46846700

Mankind Pharma - Corporate Communication

Natasha Raj

Email address: natasha.raj@mankindpharma.com

Contact Number: 011-46846700 Ext: 3201

Adfactors PR - Investor Relations / Public Relations

Smit Shah / Apoorva Sharma

Email address: smit.shah@adfactorspr.com / apoorva.sharma@adfactorspr.com

Contact Number: +91 9870789596 / +91 9999739452